The use of Artificial Intelligence (AI) in the context of Real World Evidence (RWE) is generating excitement because it has the potential to transform the way healthcare is delivered and improve patient outcomes. RWE refers to data collected outside of the traditional clinical trial setting, such as electronic health records, claims data, and patient-generated data. This data provides valuable insights into how drugs and medical devices perform in real-world settings and how they impact patient health.
AI has the ability to rapidly analyze large volumes of complex data from multiple sources and identify patterns and insights that can help healthcare providers make better treatment decisions. For example, AI can help identify patient populations who may benefit most from a particular treatment, or it can help identify adverse events associated with a medication or medical device that may not have been detected in clinical trials.
The use of AI in RWE can also lead to cost savings by identifying more efficient and effective treatment options, reducing the need for trial-and-error treatments, and avoiding unnecessary procedures and tests.
Overall, the excitement surrounding the use of AI in RWE is due to its potential to improve patient outcomes, enhance healthcare delivery, and reduce costs.
Share this story...
Real World Evidence (RWE) 101 – Patient Retention
RWE 101 - Patient Retention Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:[1] Time Commitment: Participants in RWE studies are [...]
Real World Evidence (RWE) 101 – Patient Recruitment
RWE 101 - Patient Recruitment Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic [...]
Real World Evidence (RWE) 101 – HARPER
RWE 101 - HARPER Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or [...]
Real World Evidence (RWE) 101 – STaRT-RWE
RWE 101 - STaRT-RWE START-RWE (Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies) was developed to address the need for improved transparency and [...]
Real World Evidence (RWE) 101 – Protocol Design and ISPE GPP
RWE 101 - Protocol Design and ISPE GPP The International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) are a set of best practices for the conduct [...]
Real World Evidence (RWE) 101 – Protocol Design and Scientific Best Practices
RWE 101 - Protocol Design and Scientific Best Practices Designing a robust Real-World Evidence (RWE) study is crucial for generating reliable and valid insights that are acceptable to regulators. [...]







